Prognostic effect of categorized tumor deposits in gastric cancer: A single-center retrospective study

Hayashi, Masato; Abe, Makoto; Fujita, Takeshi; Matsushita, Hisayuki

doi:10.1016/j.surg.2023.09.039

Cited by 1 publication

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, targeted therapy and immunotherapy currently have significant limitations, including drug resistance, strict eligibility criteria, and high costs[ 55 , 56 ]. As a result, chemotherapy remains the most commonly used treatment during the perioperative period for GC[ 7 , 57 ]. This study aimed to identify an optimal regimen for enhancing the survival outcomes of patients with locally resectable GC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of perioperative therapy for locally resectable gastric cancer: A network meta-analysis of randomized clinical trials

Kuang,

Sun,

Cao

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

BACKGROUND Gastric cancer (GC) is the fifth most commonly diagnosed malignancy worldwide, with over 1 million new cases per year, and the third leading cause of cancer-related death. AIM To determine the optimal perioperative treatment regimen for patients with locally resectable GC. METHODS A comprehensive literature search was conducted, focusing on phase II/III randomized controlled trials (RCTs) assessing perioperative chemotherapy and chemoradiotherapy in treating locally resectable GC. The R0 resection rate, overall survival (OS), disease-free survival (DFS), and incidence of grade 3 or higher nonsurgical severe adverse events (SAEs) associated with various perioperative regimens were analyzed. A Bayesian network meta-analysis was performed to compare treatment regimens and rank their efficacy. RESULTS Thirty RCTs involving 8346 patients were included in this study. Neoadjuvant XELOX plus neoadjuvant radiotherapy and neoadjuvant CF were found to significantly improve the R0 resection rate compared with surgery alone, and the former had the highest probability of being the most effective option in this context. Neoadjuvant plus adjuvant FLOT was associated with the highest probability of being the best regimen for improving OS. Owing to limited data, no definitive ranking could be determined for DFS. Considering nonsurgical SAEs, FLO has emerged as the safest treatment regimen. CONCLUSION This study provides valuable insights for clinicians when selecting perioperative treatment regimens for patients with locally resectable GC. Further studies are required to validate these findings.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Gastroesophageal reflux disease is also linked to gastric-esophageal junction cancers[ 6 ]. Although the global incidence of GC has declined due to improved living conditions and early screening[ 2 ], the number of new cases and deaths remains significant, likely due to population growth and aging[ 7 ].…”

Section: Introductionmentioning

confidence: 99%